Real questions from health communities, answered with cited research from PubMed and Vellito's article corpus. Plain language, no medical advice. How this works.
Yes, CAR-T cell therapy is highly effective for hematologic malignancies, with success in blood cancers like ALL, but faces challenges in solid tumors.
For high-risk GIST patients, 5-year relapse-free survival is about 74% with ≤3 years of adjuvant imatinib and 84% with >3 years, based on a 2026 retrospective study.
Treatment with eltrombopag and immunosuppression leads to an increase in clonal mutations over time, with two main patterns of evolution: early changes involving chromosome 7 and…
Yes, longitudinal TCR profiling can predict GVHD in stem cell transplant patients, with studies showing AUC values around 0.83 for GVHD prediction.
Frontline ATRA-ATO therapy is highly effective for newly diagnosed APL, with complete remission rates over 94% and 3-year survival above 93% in clinical trials.
Yes, Rytelo (imetelstat) is FDA-approved for adults with low- to intermediate-1 risk MDS and transfusion-dependent anemia who need ≥4 RBC units over 8 weeks and have not…
Yes, Revlimid (lenalidomide) is FDA-approved for transfusion-dependent anemia in low- or intermediate-1-risk MDS with a deletion 5q abnormality.
Yes, the FDA approved Rytelo (imetelstat) in June 2024 for adults with low- to intermediate-1 risk MDS who have transfusion-dependent anemia and have not responded to or are…
Patients with VEXAS syndrome often respond quickly to corticosteroids but struggle with long-term dependence. Hypomethylating agents like azacitidine show gradual, sustained…
A Chinese study of 16 patients found that p.M41V is the dominant UBA1 mutation, and most showed typical symptoms like anemia, skin lesions, and ear inflammation, similar to…
All available studies on VEXAS syndrome included only male patients, so researchers could not compare treatment responses between men and women.
About 1.2% of leukemia patients experience retinal vein occlusion, according to a meta-analysis of 1,016 participants.
Research shows that high birth weight, maternal diabetes, hypertension, history of abortion, and cesarean sections are linked to a higher risk of childhood acute leukemia.
A specific case report shows that combining azacytidine with ruxolitinib helped a patient with connective tissue disease, CMML, and myelofibrosis by reducing fever, correcting…
A lower neutrophil-to-lymphocyte ratio (NLR) before starting immune therapy predicts longer survival and better response rates in metastatic cervical cancer, while a higher ratio…
CMML can be misdiagnosed as ITP when thrombocytopenia is the first symptom; immunosuppressive therapy may temporarily raise platelets, but the underlying CMML progresses…
Hematopoietic stem cell (HSC) therapies can reset the immune system to stop autoimmune attacks, though they carry risks like infection and require careful nutrition and monitoring.
Yes, Lynch syndrome increases the risk of bladder and kidney cancers, especially in people with MSH2 mutations.
Gene therapy reduces annualized bleeding rates in adults with severe Hemophilia A by a standardized mean difference of -0.72 compared to standard factor treatment, though…
Non-clotting factor therapies like emicizumab and concizumab are effective for preventing bleeding in both Hemophilia A and Hemophilia B.
Yes, non-clotting factor therapies like emicizumab and concizumab significantly reduce bleeding rates in people with congenital Hemophilia A compared to no treatment or standard…
Commercial lab data shows a rise in human parvovirus B19 detection rates in 2024 compared to 2018-2019, with further increases in antibody positivity noted in early 2025.
The Hong Kong consensus recommends immunotherapy-based combinations for first-line metastatic renal cell carcinoma, active surveillance for select patients, and specific…
In relapsed/refractory multiple myeloma patients taking teclistamab, about 57% experience any infection and about 28% have a severe (grade ≥3) infection, based on a meta-analysis.
We pull real patient questions from public Reddit health communities (r/AskDocs, r/diabetes, r/menopause, etc.). Each question is rewritten into a generic medical question (no personal details), then answered by an AI using only cited sources from Vellito's article database and PubMed. A second AI independently scores each answer for accuracy and citation fidelity before publication. Answers below the safety threshold or touching emergency, dosing, or pediatric topics are queued for human review and never auto-published.
This is not medical advice. Always speak with your own doctor before making decisions about your health.